okyopharma.com (OKYO) - Koefisien utang jangka dawa marang modal

OKYO Pharma Limited (OKYO) is developing partnerships with ophthalmology clinics to create anti-inflammatory drops. The share of long-term liabilities in equity allows for the tracking of credit load stabilization, with the current figure standing at 0.00. The company is investing in next-generation peptide inhibitors, creating innovative corneal therapy. The development of drugs to combat dry eye syndrome provides access to a multi-billion dollar market.

The lack of commercial products at OKYO Pharma Limited (OKYO) limits the company's current pricing power. Under these conditions, the share of long-term loans within the capital structure on GURU.Markets demonstrates the biotech's dependence on borrowed funds. This metric is calculated as the ratio of long-term liabilities to equity, measuring financial autonomy. The trend of this indicator reflects the balance between investments in clinical trials and the debt load, which directly impacts the final market capitalization.